{"brief_title": "Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus", "brief_summary": "This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response study to examine the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be individuals with type 2 diabetes treated with metformin for at least 3 months prior to screening. Patients whose diabetes management consists of diet and exercise will also be eligible for this study.", "condition": "Diabetes Mellitus, Non-Insulin-Dependent", "intervention_type": "Drug", "intervention_name": "AC2993 10.0 mcg", "description": "2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily", "arm_group_label": "AC2993 10.0 mcg", "other_name": "synthetic exendin-4", "criteria": "Inclusion Criteria: - Subjects with type 2 diabetes - Treated with diet and exercise alone or with metformin for at least 3 months prior to screening - BMI 27-45 kg/m^2 - HbA1c between 7.0 % and 8.0 % Exclusion Criteria: - Treated with other oral anti-diabetic agents other than metformin within 3 months of screening - Patients previously treated with AC2993 - Patients presently treated with insulin", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "id": "NCT00044694.xml"}